What is SiSaf?
SiSaf Ltd operates at the intersection of material science and molecular biology, specializing in the development of RNA therapeutics for high-unmet-need conditions such as pancreatic cancer, metastatic cancer, and osteopetrosis. Central to its market position is the proprietary Bio-Courier technology, a sophisticated delivery system that integrates bioabsorbable silicon with organic materials. This innovation addresses one of the most significant hurdles in modern medicine: the efficient and targeted delivery of nucleic acids into human cells.
By maintaining state-of-the-art research and manufacturing facilities in England, SiSaf maintains rigorous control over its development lifecycle. The company's focus on both oncology and musculoskeletal disorders positions it as a versatile entity within the biopharmaceutical industry, capable of pivoting its platform technology to address a wide array of genetic and chronic diseases.
How much funding has SiSaf raised?
SiSaf has raised a total of $16.7M across 2 funding rounds:
Series A
$3.5M
Series B
$13.2M
Series A (2016): $3.5M with participation from Vickers Venture Partners and Exen Capital
Series B (2020): $13.2M led by Future Fund and Vickers Venture Partners
Key Investors in SiSaf
Vickers Venture Partners
A global venture capital firm specializing in deep tech investments with a proven track record of scaling high-growth companies across international markets.
Future Fund
Australia's sovereign wealth fund, established to manage long-term financial assets and support the nation's public sector superannuation liabilities.
Exen Capital
An investment firm with a presence in New York, Dallas, and London, focusing on strategic venture capital, private equity, and yield-generating middle-market strategies.
What's next for SiSaf?
Looking ahead, the infusion of capital from recent funding rounds will likely be directed toward scaling the manufacturing of its Bio-Courier platform and advancing its lead candidates through critical clinical trial milestones. As the company transitions into a more advanced lifecycle stage, the focus will shift toward regulatory engagement and potential strategic partnerships with larger pharmaceutical entities to facilitate commercialization.
The firm's ability to attract high-caliber institutional backing suggests a long-term commitment to disrupting traditional therapeutic delivery methods. Investors are closely monitoring SiSaf's progress in translating its laboratory successes into viable, scalable clinical treatments, which could redefine the standard of care for patients suffering from aggressive malignancies and degenerative bone conditions.
